IMS: scan the Chinese hospital medicine market in the second quarter of 2014

Source: according to statistics on the overall market performance of Ames on October 22, 2014, the total sales volume of China's hospital medicine market in the second quarter of 2014 was 154.56 billion yuan (data source: IMS Ames China Hospital Medicine statistical report ≥ 100 beds), with a growth rate of 11.5% compared with the same period last year, slightly lower than the previous quarter Based on the 12-month mat (rolling full year data), the mat growth rate in the second quarter of 2014 was 13.1%, slightly lower than the 13.7% in the previous quarter The growth rate of China's drug sales market continues to slow down under the influence of many macro policies, including the further control of medical institutions' drug costs by the medical insurance department, and the increased supervision of rational drug use as the key influencing factors, making the hospital as a whole more conservative in drug use, directly affecting the sales changes of the whole market Sales: purchase amount of hospital pharmacy Mat (rolling annual data): the sum of data traced back 12 months from the specified time node, which refers to the sales volume from the third quarter of 2013 to the second quarter of 2014 The market performance of multinational enterprises and domestic enterprises in the second quarter of 2014 saw a growth rate of 12.3% for multinational enterprises and 11.3% for local enterprises In the overall sales ranking of pharmaceutical enterprises, Pfizer still maintains its leading position in the Chinese hospital pharmaceutical market, AstraZeneca ranks second, Qilu pharmaceutical ranks third with a sales volume of 2.75 billion yuan, which continues the best ranking of local enterprises in China Meanwhile, Kelun, Yangzi River and Hengrui still rank in the top 10 In terms of rolling annual data, the ranking is basically the same as quarterly ranking In the context of the whole Chinese pharmaceutical market, the market performance of multinational enterprises will be restricted by the macro policies on drug prices and drug consumption for a long time, coupled with the drag of GlaxoSmithKline, which seriously affects the overall growth trend of the pharmaceutical industry, even local enterprises are no exception Pfizer's performance is mainly due to the long-term and stable contribution of cardiovascular drugs, in line with the government's goal of better management of chronic diseases In six provinces of Shandong, Henan, Jiangsu, Zhejiang, Guangdong and Sichuan, which can cover 40% of the hospital channel sales in China, multinational enterprises have outstanding performance in Guangdong and Zhejiang, all of which can reach more than 30% market share Two thousand and fourteen In the second quarter of, from the perspective of city level, first tier and second tier cities are the key areas of multinational enterprises, but the growth rate of multinational enterprises in low-level cities is higher than that in first tier and second tier cities, which shows that multinational enterprises are exploring the market of low-level cities; for local enterprises, low-level cities contribute more sales, while they show higher performance in first tier and second tier cities The growth rate of Comparison of drug sales between multinational and local enterprises in various treatment fields from the perspective of products, in the second quarter of 2014, only four products of multinational enterprises entered the list of top ten products, and the rest were products of local enterprises The top three products of local enterprises are Shenjie, with a quarterly sales volume of 99.9 million yuan, ranking first in hospital medication; Xueshuantong, with a quarterly sales volume of 94.5 million yuan, ranking second, down one place compared with the first quarter; odegin of AoHong in Jinzhou, replacing poliway of Sanofi, rose to third place At present, Chinese patent medicine has become the largest treatment field in Chinese hospital market Sales in the second quarter of 2014 were 30.77 billion yuan, an increase of 10.2% The growth rate of systemic anti infective products was 8.2%, and that of digestive and metabolic drugs was 13.1%.